ES2721525T3 - Novedosos agonistas de EP4 como compuestos terapéuticos - Google Patents

Novedosos agonistas de EP4 como compuestos terapéuticos Download PDF

Info

Publication number
ES2721525T3
ES2721525T3 ES15744724T ES15744724T ES2721525T3 ES 2721525 T3 ES2721525 T3 ES 2721525T3 ES 15744724 T ES15744724 T ES 15744724T ES 15744724 T ES15744724 T ES 15744724T ES 2721525 T3 ES2721525 T3 ES 2721525T3
Authority
ES
Spain
Prior art keywords
group
alkyl
agonists
novel
och3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15744724T
Other languages
English (en)
Inventor
David W Old
christopher d Hein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2721525T3 publication Critical patent/ES2721525T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto que tiene la siguiente estructura: **(Ver fórmula)** o una sal o diastereoisómero o enantiómero farmacéuticamente aceptable de los mismos, en donde: la línea discontinua es un enlace simple o doble; Y es H o CH3; X es cero, uno o dos sustituyentes en el anillo de cicloalcano o cicloalqueno, seleccionados dichos sustituyentes del grupo que consiste en H, alquilo C1 - C6, hidroxialquilo, arilo, halógeno, cicloalqueno, CF3, C(O)R, COCF3, SO2N(R)2, SO2NH2, NO2, y CN; n se selecciona del grupo que consiste en 0, 1, 2, 3, o 4; R es alquilo C1 - C6; R2 se selecciona del grupo que consiste en H, alquilo C1 - C6, hidroxialquilo, fenilo o bifenilo; R3 es forma selecciona el grupo que consiste en H, C(O)R5, SO2R5, alquilo C1 - C6; R5 es alquilo C1-C6, haloalquilo incluido trifluorometilo, arilo o heteroarilo; R6 es CO2H, CH3, CO2R2, CH2OR2, CONR2R3 o tetrazol-5-ilo; R7 se selecciona del grupo que consiste en H, CF3, OCH3; y R8 es forma selecciona el grupo que consiste en H y OCH3.
ES15744724T 2014-06-06 2015-06-05 Novedosos agonistas de EP4 como compuestos terapéuticos Active ES2721525T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462009028P 2014-06-06 2014-06-06
PCT/US2015/034566 WO2015188152A1 (en) 2014-06-06 2015-06-05 Novel ep4 agonists as therapeutic compounds

Publications (1)

Publication Number Publication Date
ES2721525T3 true ES2721525T3 (es) 2019-08-01

Family

ID=53762282

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15744724T Active ES2721525T3 (es) 2014-06-06 2015-06-05 Novedosos agonistas de EP4 como compuestos terapéuticos

Country Status (13)

Country Link
US (2) US9926262B2 (es)
EP (1) EP3152188B1 (es)
JP (1) JP6588475B2 (es)
KR (1) KR20170010059A (es)
CN (1) CN106458859B (es)
AU (1) AU2015269064B2 (es)
BR (1) BR112016028614A8 (es)
CA (1) CA2953218A1 (es)
DK (1) DK3152188T3 (es)
ES (1) ES2721525T3 (es)
RU (1) RU2016150902A (es)
TR (1) TR201905436T4 (es)
WO (1) WO2015188152A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2015188152A1 (en) 2014-06-06 2015-12-10 Allergan, Inc. Novel ep4 agonists as therapeutic compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4540690A (en) * 1982-02-09 1985-09-10 The Upjohn Company 2-(Phenylmethylene)cycloalkylamines and -azetidines
US5420343A (en) 1994-08-31 1995-05-30 G. D. Searle & Co. Derivatives of aromatic cyclic alkylethers
US6586468B1 (en) 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
DE60009883T2 (de) * 1999-03-01 2005-04-07 Elan Pharmaceuticals, Inc., San Francisco Alpha-aminoessigsäure derivate als alpha 4 beta 7- rezeptor antagonisten
SK5562003A3 (en) 2000-11-27 2004-08-03 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
WO2002102389A1 (en) 2001-06-14 2002-12-27 Allergan, Inc. 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
EP1591441A4 (en) 2003-02-07 2007-10-31 Ono Pharmaceutical Co CARBON ACID COMPOUNDS
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7427685B2 (en) 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US7476755B2 (en) * 2006-05-04 2009-01-13 Allergan, Inc. Therapeutic compounds
AU2007261034B2 (en) * 2006-06-20 2012-09-13 Allergan, Inc. Therapeutic compounds
AU2007272683B2 (en) 2006-07-10 2012-08-23 Allergan, Inc. Substituted cyclopentane derivatives as therapeutic agents
CA2657719C (en) 2006-07-11 2015-12-29 Allergan, Inc. Cyclopentane derivatives as antiglaucoma agents
US20080015219A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Therapeutic compounds
JP5259592B2 (ja) * 2006-08-11 2013-08-07 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体
US10052299B2 (en) 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
WO2013004291A1 (en) * 2011-07-04 2013-01-10 Rottapharm S.P.A. Cyclic amine derivatives as ep4 receptor agonists
WO2015188152A1 (en) 2014-06-06 2015-12-10 Allergan, Inc. Novel ep4 agonists as therapeutic compounds

Also Published As

Publication number Publication date
CN106458859B (zh) 2019-08-30
US20170183293A1 (en) 2017-06-29
US9926262B2 (en) 2018-03-27
US10407382B2 (en) 2019-09-10
BR112016028614A8 (pt) 2021-04-06
EP3152188B1 (en) 2019-02-13
AU2015269064A1 (en) 2016-12-22
TR201905436T4 (tr) 2019-05-21
EP3152188A1 (en) 2017-04-12
WO2015188152A1 (en) 2015-12-10
BR112016028614A2 (pt) 2017-08-22
US20180170858A1 (en) 2018-06-21
JP6588475B2 (ja) 2019-10-09
DK3152188T3 (en) 2019-04-29
KR20170010059A (ko) 2017-01-25
RU2016150902A (ru) 2018-07-17
AU2015269064B2 (en) 2020-02-13
JP2017518317A (ja) 2017-07-06
RU2016150902A3 (es) 2018-12-19
CN106458859A (zh) 2017-02-22
CA2953218A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
AR098912A1 (es) Inhibidores de syk
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
SV2016005328A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
ES2659397T3 (es) 2-azabicíclicos sustituidos y su uso como moduladores receptores de orexinas
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
AR099400A1 (es) Compuesto heterocíclico fusionado
RS52261B (en) AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR
AR095421A1 (es) Moduladores de p2x7
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
CL2020002588A1 (es) Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016)
AR085327A1 (es) Inhibidores del virus de la hepatitis c
AR097866A1 (es) Derivados de 4-azaindol
AR101132A1 (es) Derivados de pirazina agonistas del gpr40 para el tratamiento de la diabetes tipo ii
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
RS54730B1 (sr) Inhibitori beta sekretaze
AR083903A1 (es) Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos
MY169179A (en) Novel piperidine compound or salt thereof
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR098522A1 (es) Compuesto de triazolo-piridina
AR100439A1 (es) Derivados de carboxamida